Patients’ characteristics
AKI, µmol/LChronic kidney disease
RENAL DISEASE
In the main trial, 1329 patients were randomized: 645 to receive high-dose protein and 656 to receive usual-dose protein. In the high-protein group, 163 (25.3%) patients had AKI while in the usual care group, 149 (22.7%) had AKI. In total, 312 patients developed AKI within the first 7 days in the ICU were included in this analysis, whereby 120 (38.5%), 74 (23.7%), 118 (37.8%) were AKI stage I, II and III, respectively (Fig. Flow chartBaseline demographics in AKI patientsValues reported as n (%), (n) mean ± SD (min–max)*Acute kidney injury: KDIGO Stage 1: ≥ 26.52 µmol/L increase within 48 h or 1.5–1.9 times baseline within 7 days; Stage 2: 2.0–2.9 times baseline within 7 days; Stage 3: ≥ 3 times baseline within 7 days or increase to ≥ 353.6 µmol/L with an acute increase of > 44.2 µmol/LChronic kidney disease: Defined in comorbidities as moderate renal disease: creatinine clearance 51–85 mL/min; and severe renal disease: creatinine clearance less than 50 mL/min and not on dialysis